Allan-Herndon-Dudley syndrome is a rare congenital disease of thyroid metabolism. It occurs in approximately 1 out of every 70,000 male newborns, and its effects are devastating. Since early 2025, a medication has been approved in Europe that can alleviate symptoms and extend patients' life expectancy. However, the dosage is complicated.
Source: Medical Xpress
